Table 4.

Cox model for event-free survival (timed from surgery) for all ‘M0-CSR’ patients (N = 1395).

Characteristic	N	EFS events	Adjusted HR (95% CI)	p-value	Overall p-value
Site of the tumour
Other limb site	1175	382	1.00	n/a	0.039
Proximal femur/humerus	166	72	1.38 (1.06–1.80)	0.018
Axial skeleton	54	27	1.29 (0.86–1.95)	0.214
WHO classification of sarcoma at diagnosis
Conventional: chondroblastic	240	103	1.00	n/a	0.157
Conventional: osteoblastic	830	284	0.91 (0.72–1.14)	0.408
Conventional: other	230	69	0.71 (0.52–0.96)	0.029
Telangiectatic	69	18	0.71 (0.42–1.20)	0.199
Small cell	6	2	0.79 (0.19–3.20)	0.737
High-grade surface	20	5	0.45 (0.18–1.12)	0.086
Age
Child	409	110	1.00	n/a	0.003
Adolescent	689	250	1.43 (1.14–1.79)	0.002
Adult	297	121	1.53 (1.17–1.99)	0.002
Gender
Female	586	189	1.00	n/a	0.071
Male	809	292	1.19 (0.99–1.43)	0.071
Relative tumour volumea
Small (<1/3 of the involved bone)	679	214	1.00	n/a	0.046
Large (≥1/3 of the involved bone)	476	197	1.24 (1.00–1.52)	0.046
Pathological fracture at diagnosis
No	1235	426	1.00	n/a	0.783
Yes	160	55	0.96 (0.71–1.29)	0.783
Surgical margins achievedb
Wide/Radical	1200	403	1.00	n/a	0.201
Marginal	182	71	1.11 (0.83–1.49)	0.482
Intralesional	13	7	1.98 (0.91–4.30)	0.083
Histological response
Good (<10% viable tumour)	724	176	1.00	n/a	<0.001
Poor (≥10% viable tumour)	671	305	2.13 (1.76–2.58)	<0.001

CI, confidence interval; EFS, event-free survival; HR, hazard ratio; WHO, World Health Organisation.

^a240 missing values imputed.

^bas reported by the pathologist.